Ifabotuzumab, CAS 2147698-66-4

Product Description: Ifabotuzumab (KB004) is an IgG1κ antibody targeting EphA3 (KD=610 pM). Ifabotuzumab induces tumor cell apoptosis, activates Antibody-dependent cell mediated cytotoxicity (ADCC), and damages tumor vasculature. Ifabotuzumab reduces human idiopathic pulmonary fibrosis (IPF) CCR10+ cells and improves pulmonary fibrosis[1][2].

Applications: Cancer-Kinase/protease

Formula: N/A

References: [1]Hohmann MS, et al. Antibody-mediated depletion of CCR10+EphA3+ cells ameliorates fibrosis in IPF. JCI Insight. 2021 Jun 8;6(11):e141061./[2]Swords R T,et al. KB004, a novel non-fucosylated humaneered® antibody, targeting EphA3, is active and well tolerated in a phase I/II study of advanced hematologic malignancies[J]. Blood, 2014, 124(21): 3756.

CAS Number: 2147698-66-4

Molecular Weight: N/A

Compound Purity: 95.0

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: Apoptosis;Ephrin Receptor

• Artikelnummer: MEXHY-P99655-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99655-5
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated